1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Search
trust-through-transparency
Transparency is an essential cornerstone of trust in the healthcare industry
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Ridgefield
Ridgefield is home to the company’s US headquarters. The site serves as a key research center for human pharmaceuticals.
Koropi
For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Yamagata
The site in Yamagata, Japan, is dedicated to the production of human pharmaceutical products for the Japanese market.
Sant Cugat del Vallès
The site in Sant Cugat del Vallès focuses on pharmaceutical production and is one of the production sites of the RESPIMAT®.
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
More health in vulnerable communities
In an era of globalization and social connectivity, one-dimensional solutions often do not work anymore. Complex challenges need complex solutions.
Fornovo
With its production facilities, Fornovo San Giovanni constitutes an important site for the production of core active pharmaceutical ingredients for both Human Pharma and Animal Health.
EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
MORE GREEN: Reducing emissions throughout the supply chain
How Thermo Fisher is contributing to the decarbonization of Boehringer Ingelheim’s supply chain by reducing their own emissions
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Newsbits
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Innovation and drone delivery
Addressing healthcare disparities through collaborative innovation and drone delivery
Excellence in innovation | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's commitment to innovation in pharmaceutical production, delivering cutting-edge solutions for your biopharmaceutical needs.